Skip to main content
Journal cover image

The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.

Publication ,  Journal Article
Chambers, HF; Cross, HR; Souli, M; Evans, SR; Patel, R; Fowler, VG; Antibacterial Resistance Leadership Group,
Published in: Clin Infect Dis
October 16, 2023

In this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 16, 2023

Volume

77

Issue

Suppl 4

Start / End Page

S279 / S287

Location

United States

Related Subject Headings

  • Microbiology
  • Microbial Sensitivity Tests
  • Leadership
  • Humans
  • Drug Resistance, Bacterial
  • Colistin
  • Ceftazidime
  • Carbapenems
  • Anti-Bacterial Agents
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chambers, H. F., Cross, H. R., Souli, M., Evans, S. R., Patel, R., Fowler, V. G., & Antibacterial Resistance Leadership Group, . (2023). The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clin Infect Dis, 77(Suppl 4), S279–S287. https://doi.org/10.1093/cid/ciad475
Chambers, Henry F., Heather R. Cross, Maria Souli, Scott R. Evans, Robin Patel, Vance G. Fowler, and Vance G. Antibacterial Resistance Leadership Group. “The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.Clin Infect Dis 77, no. Suppl 4 (October 16, 2023): S279–87. https://doi.org/10.1093/cid/ciad475.
Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG, et al. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S279–87.
Chambers, Henry F., et al. “The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.Clin Infect Dis, vol. 77, no. Suppl 4, Oct. 2023, pp. S279–87. Pubmed, doi:10.1093/cid/ciad475.
Chambers HF, Cross HR, Souli M, Evans SR, Patel R, Fowler VG, Antibacterial Resistance Leadership Group. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S279–S287.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

October 16, 2023

Volume

77

Issue

Suppl 4

Start / End Page

S279 / S287

Location

United States

Related Subject Headings

  • Microbiology
  • Microbial Sensitivity Tests
  • Leadership
  • Humans
  • Drug Resistance, Bacterial
  • Colistin
  • Ceftazidime
  • Carbapenems
  • Anti-Bacterial Agents
  • 3202 Clinical sciences